Episode
Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness
- Podcast
- Cell & Gene: The Podcast
- Published
- Feb 12, 2026
- Duration seconds
- 860
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/inside-a-breakthrough-her2-immunotherapy-for-pmo-with-os-therapies-paul-romness/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/cell-gene-the-podcast-4048431/inside-a-breakthrough-her2-immunotherapy-for-pmo-with-os-therapies-paul-romness.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies’ off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust im...